TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable or non-dilatable lesions, as it allows for calcium ablation or fracturing. 

TCT 2024 | Utilización de balones cubiertos de fármacos para el tratamiento de la rama lateral en técnica de stent provisional

The ECLIPSE study, a randomized trial, compared orbital atherectomy (OA) with balloon angioplasty (including cutting and scoring balloons) for the treatment of severely calcified lesions before drug-eluting stent (DES) implantation.

This study included patients with chronic and acute coronary syndromes (without ST elevation) and de novo lesions with severe calcification, as determined by angiography or intravascular ultrasound (IVUS)/optical coherence tomography (OCT), where plaque preparation was feasible with either therapy. 

A total of 2005 patients were enrolled across 104 US centers. Randomization was 1:1. The primary endpoints were (1) imaging analysis assessing minimal stent area (MSA) post-PCI, and (2) target vessel failure (TVF) at one year.

The average participant age was 69.9 years; 73.6% of subjects were men, and 23% had chronic kidney disease.

Read also: TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE.

In terms of the procedure, 47.6% of the orbital atherectomy group was treated via transfemoral access, 4.6% required a temporary pacemaker, 21.4% needed an extension catheter, and 42% used an OTW microcatheter or balloon. Intravascular imaging was used in 62.1% of procedures (40.3% of cases used OCT and 25.6%, IVUS).

In an analysis of the complications, there were low rates of no-reflow (0.3% vs 0.1%), type C-F dissections (6.9% vs 6.3%), and perforations (1.8% vs 1%, mostly Ellis type III). The incidence of slow flow was higher in the OA group (1.4% vs 0.4%; p=0.03). 

MSA in the most calcified region was 7.44 vs 7.05, a non-significant difference (-0.26 mm²; p=0.08). Regarding TVF at 1 year, orbital atherectomy showed an incidence of 11.5% vs 10.0% (hazard ratio [HR] 1.16; 95% confidence interval [CI] 0.87-1.54; p=0.28). 

Read also: TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting.

Regarding secondary endpoints, the OA group had higher cardiovascular mortality (p=0.005) and both groups had a similar stent thrombosis rate (0.7% vs 0.3%).

The authors concluded that routine use of orbital atherectomy did not improve MSA or reduce TVF compared with balloon PCI.

Presented by Ajay J Kirtane in the Late-Breaking Trials Sessions, TCT 2024, October 27-29, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...